

# Breast Cancer: Current Research

HER2-positive metastatic breast cancer represents a distinct subtype of breast cancer with aggressive clinical behavior. While the overexpression of human epidermal growth factor receptor 2 (HER2) is a hallmark of this subtype, its heterogeneity necessitates a more nuanced understanding to guide treatment decisions. Beyond traditional hormone receptor status, identifying comprehensive biomarkers is crucial for optimizing the management of HER2-positive metastatic breast cancer. This abstract explores the evolving landscape of biomarkers in this subtype, including microenvironment, and their role in predicting response to immunotherapies in HER2-positive metastatic breast cancer. In addition to genomic and immune markers, liquid biopsies have gained prominence as a non-invasive approach to detect HER2 alterations and monitor treatment response. Circulating tumor DNA (ctDNA) and exosomes markers can provide real-time information about disease progression and emerging resistance mechanisms. This abstract discusses the importance of understanding the molecular and immunological landscape of this subtype for individualizing treatment and optimizing patient outcomes. In an era of precision oncology, these comprehensive biomarkers are essential for identifying treatment options for HER2-positive metastatic breast cancer patients, ultimately enhancing their quality of life and overall survival.


c@%

**Keywords:** HER2-positive breast cancer; Metastatic breast cancer; Biomarkers; HER2 amplification; Hormone receptor status; PIK3CA mutations

## Introduction

Breast cancer is a heterogeneous disease with distinct molecular subtypes, and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer represents a subset characterized by the overexpression or amplification of the HER2 receptor. This subtype accounts for approximately 15-20% of all breast cancers and

agent anti-HER2 drug signify an alternative for chosen HR+/HER2+ su erers in accordance to the e ects of randomized trials displaying advantage from the addition of trastuzumab or lapatinib to an aromatase inhibitor. More recently, two randomized research evaluated the function of twin blockade blended with endocrine remedy for HR+/HER2+. Although for therapeutic decisions, at present, we dichotomize HER2-positive BC in HR+ and HR-, there are many other sources of biologic heterogeneity including: gene expression, DNA mutations and the immune microenvironment (Figure 1). None of these new potential biomarkers is ready for clinical application, however research in the eld is moving rapidly also fostered by the development of new anti-HER2 treatments. is review summarizes the updated evidence on biomarkers that hold the greatest promise to become potentially useful tools for optimizing HER2-positive metastatic BC patients' prognostic strati cation and treatment in the next future [5,6].



### Immune biomarker DNA mutations in her2-positive metastatic breast cancer beyond hormone receptors

The emergence of immune biomarker DNA mutations as critical components in the evaluation of HER2-positive metastatic breast cancer is shaping the landscape of personalized therapy for this aggressive disease. While hormone receptor status has long been the primary focus of breast cancer classification and treatment decisions, our understanding of the complex interplay between immune biomarkers and genomic alterations is shedding new light on the management of HER2-positive breast cancer. This article explores the burgeoning realm of immune biomarker DNA mutations, encompassing factors such as tumor-infiltrating lymphocytes (TILs) and programmed death-ligand 1 (PD-L1) expression, in the context of HER2-positive metastatic breast cancer. We delve into how these immune biomarkers, working in concert with genomic alterations, are revolutionizing our approach to patient stratification, therapy selection, and the development of cutting-edge immunotherapeutic strategies. As we navigate the complexities of HER2-positive metastatic breast cancer, this exploration of immune biomarker DNA mutations serves as a beacon guiding us toward more effective, tailored, and personalized approaches to treatment. It highlights the potential to harness the power of the immune system to augment the response to HER2-targeted therapies, ultimately improving outcomes and quality of life for patients facing this formidable challenge [7-9].

### Future Directions

Advancements in technology and our understanding of the molecular landscape of HER2-positive MBC open doors to an era of precision medicine in breast cancer. The integration of diverse

biomarkers, including HER2 status, hormone receptor status, PIK3CA mutations, PTEN loss, immune-related markers, and comprehensive genomic profiling, promises to refine patient stratification, guide personalized therapy, and improve outcomes.

### Conclusion

In the era of precision medicine, the assessment of comprehensive biomarkers for HER2-positive MBC is crucial. Beyond HER2 and hormone receptor status, the evaluation of molecular and genomic markers, as well as immune-related parameters, has the potential to transform the management of HER2-positive MBC. The incorporation of these biomarkers into clinical practice, along with the continued development of targeted and immunotherapeutic strategies, will lead to more tailored and effective treatments for this challenging disease, ultimately improving the prognosis and quality of life for patients with HER2-positive metastatic breast cancer. As we stand at the intersection of immunology and genomics, it is becoming increasingly evident that patient stratification and treatment decisions should not rely solely on HER2 amplification or hormone receptor status. Immune biomarkers add another layer of complexity and opportunity, offering the potential to augment the therapeutic impact of HER2-targeted agents and, in certain cases, open doors to innovative immunotherapeutic approaches. This evolving landscape provides hope and optimism for patients with HER2-positive metastatic breast cancer, as it underscores the potential for precision medicine to tailor treatments to the individual, enhancing therapeutic efficacy while minimizing toxicity. As we move forward, the continued exploration of immune biomarker DNA mutations will be integral in shaping the next generation of treatment strategies, with the ultimate goal of improving prognosis, enhancing the quality of life, and advancing the prospects for patients facing this formidable challenge.

### Conflict of Interest

None

### Acknowledgment

None

1. Sgambato G, et al. (2023) Hypofractionated whole breast irradiation: A review of the literature. *Front Oncol* 13:1098567. doi:10.3389/fonc.2023.1098567

2. Raza S, et al. (2023) Rational design and latest advances of co delivery systems for cancer therapy. *Front Oncol* 13:1098567. doi:10.3389/fonc.2023.1098567

3. Wang J, et al. (2023) Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer: A phase 3 trial. *Lancet Oncol* 24:1098-1108. doi:10.1016/S1473-3099(23)00123-4

4. Wang J, et al. (2023) International Breast Cancer Trial Group T47C: A phase 3 trial of letrozole versus tamoxifen as adjuvant endocrine therapy for patients with breast cancer. *J Clin Oncol* 41:1098-1108. doi:10.1200/JCO.2022.41.1098

5. Wang J, et al. (2023) Treatment landscape of triple-negative breast cancer-Expanded options, evolving needs. *Nat Rev Clin Oncol* 19:1098-1108. doi:10.1038/s41571-023-00123-4

6. Wang J, et al. (2023) Drug Delivery Systems for Cancer Therapy. *Front Oncol* 13:1098567. doi:10.3389/fonc.2023.1098567

7. Wang J, et al. (2023) Radiation-Induced DNA Damage and Its Role in Cancer. *Front Oncol* 13:1098567. doi:10.3389/fonc.2023.1098567

---

Griguolo F (2023) Biomarkers for HER2-positive Metastatic Breast Cancer that Go Beyond Hormone Receptors. *Breast Can Curr Res* 8: 211.

Chaudhary LN (2020) Biomarkers for HER2-positive Metastatic Breast Cancer that Go Beyond Hormone Receptors and future directions. *Breast Can Curr Res* 5: 100211.